Lantheus (LNTH) Q4 2025 earnings review
A Painful Strategic Pivot Masks Modest Top-Line Growth
Lantheus delivered 4% YoY revenue growth in Q4 to $406.8 million, breaking a string of stagnant quarters, primarily driven by the inorganic addition of Neuraceq and milestone payments. However, the core growth engine—PYLARIFY—is broken. Despite a 4% increase in volume, PYLARIFY revenue contracted 9.7% YoY due to severe price concessions. Management is initiating a massive strategic reset: having just divested its legacy SPECT business, Lantheus now plans to abandon its radiotherapeutic pipeline to focus strictly on PET diagnostics. FY26 guidance reflects a harsh transition year, with adjusted earnings reversing lower as the company invests heavily ahead of four potential new product launches.
🐂 Bull Case
The recently acquired Alzheimer's imaging agent Neuraceq generated $31 million in Q4. With plans to expand its manufacturing network by six new sites in 2026, management expects triple-digit inorganic growth, tapping into a massive emerging market.
The company has three major PDUFA dates in 2026: a new PSMA PET formulation (March 6), OCTEVY (March 29), and MK-6240 (August 13). If approved, these diagnostics will completely re-shape the product portfolio by 2027.
🐻 Bear Case
PYLARIFY is losing its pricing power. Management deliberately walked away from some business to protect long-term pricing, resulting in a 9.7% Q4 revenue drop. FY26 guidance projects another 8-10% decline.
Adjusted EPS guidance for FY26 ($5.00-$5.25) implies a roughly 11% deceleration against normalized FY25 results ($5.75). Expanding SG&A and R&D for new product launches will severely compress margins in the near term.
⚖️ Verdict: 🔴
Bearish. While the long-term pivot to a diversified PET diagnostic portfolio makes strategic sense, the near-term execution risk is enormous. Lantheus is sacrificing current earnings and the cash cow profile of PYLARIFY to fund a highly competitive future.
Key Themes
PYLARIFY Pricing Dynamics Erode Core Revenue
The narrative that strategic contracts would insulate PYLARIFY has been definitively broken. While management noted a 4% volume increase in Q4, actual segment revenue declined 9.7% to $240.2 million. This contradicts the positive commercial execution narrative and highlights a decelerating trend caused by intense competitor discounting and a Mean Unit Cost (MUC) reimbursement environment. Management guides for an 8-10% net revenue decline in 2026, explicitly noting that competitive dynamics will worsen as a key competitor loses pass-through status in September 2026.
The 'New Formulation' Lifeboat
Lantheus is heavily banking on FDA approval (PDUFA March 6) for a new F-18 PSMA PET formulation. Crucially, this new formulation is expected to secure a new HCPCS code and three years of Transitional Pass-Through (TPT) payment status by October 2026. This would reverse the current reimbursement disadvantage and level the playing field. Commercial rollout is planned geographically in Q4 2026, meaning financial benefits won't materialize until 2027.
Strategic Abandonment of Therapeutics
In a major reversal from previous years' M&A logic (which heavily featured theragnostic pairs), Lantheus announced it will pursue 'value-maximizing alternatives' for its radiotherapeutic pipeline to focus exclusively on PET radiodiagnostics. This effectively writes down internal expectations for assets acquired from Evergreen Theragnostics, though it will structurally reduce future Phase 3 R&D burdens.
Alzheimer's Imaging is the New Growth Engine
With PYLARIFY struggling, the Alzheimer's portfolio has become the critical growth driver. Neuraceq exited 2025 as the second-most utilized amyloid PET agent in the U.S., generating $31 million in Q4. Management plans to aggressively scale the PET Manufacturing Facility (PMF) network from 16 to 22+ sites in 2026. Coupled with the upcoming PDUFA date for the MK-6240 tau-targeted agent, Lantheus is positioning itself to capture the rising diagnostic demand triggered by new Alzheimer's disease-modifying therapies.
Margin Compression Imminent
The transition year will punish margins. While gross margins are expected to remain stable at ~65.5%, management guided for R&D to increase to 10-11% of revenue (up 200 bps) and sales & marketing to expand to ~12.5% of revenue. This spending is necessary to prepare for four potential FDA approvals, but it guarantees decelerating operating leverage throughout 2026.
Other KPIs
Decelerating. Dropped 8.5% YoY, continuing a multi-quarter trend of margin compression. Adjusted operating margin fell to 34.1% from 38.8% a year ago, reflecting lower PYLARIFY net pricing and the inclusion of higher operating expenses from recent acquisitions.
Decelerating significantly from $141.4 million in the prior-year period. Management attributed the $60 million variance to working capital changes, primarily the acceleration of accounts payable tied to the cutover activities for the divested SPECT business, as well as an intentional buildup of inventory to support the expanding PMF network.
Stable. Declined 1.0% YoY, but this was strictly due to a difficult comp (Q4 2024 saw unusual spikes driven by a competitor's supply chain failure). The franchise remains highly dependable and continues to hold over 80% market share as it enters its 25th year.
Guidance
Stable. To understand this guidance, investors must strip out the divested SPECT business ($111.4M) and a one-time milestone ($6M) from the 2025 base, creating a normalized FY25 comparative of $1.424 billion. Against this base, the midpoint implies flat YoY growth, as Neuraceq's rapid expansion is completely offset by PYLARIFY's anticipated decline.
Reversing. Normalized for specific 2025 benefits (like an employee retention credit and bonus accrual reductions) and the SPECT divestiture, the FY25 comparable base is $5.75. The $5.125 midpoint represents an 11% earnings decline. The pain is driven by a $9M headwind in interest income (cash spent on M&A/buybacks) and purposeful SG&A/R&D expansion.
Decelerating aggressively. Despite modeling low-single-digit volume growth, pricing concessions to retain major accounts and broader market competition will drag net revenue down significantly. Sequential quarterly revenue is expected to be flat throughout the year as discounts widen.
Key Questions
Therapeutic Pipeline Monetization
Given the explicit shift to offload the radiotherapeutic pipeline, how should investors value the upfront investments made during the Evergreen Theragnostics acquisition? What structure (out-licensing, spin-off) is preferred?
PYLARIFY TPT Status Risk
The entire 2027 recovery narrative relies on securing Transitional Pass-Through status for the new PYLARIFY formulation. What is the contingency plan if CMS delays or denies this status?
Capital Allocation Void
With the SPECT business generating $115M historically and significant cash used for M&A, interest income has swung from a positive to a negative. Will the remainder of the $400M buyback be paused to protect the balance sheet during this transition year?